Skip to content
Amiloride
Hydro-ride, Midamor, Moduretic (amiloride) is a small molecule pharmaceutical. Amiloride was first approved as Midamor on 1982-01-01. It is used to treat ascites, cystic fibrosis, edema, heart failure, and hypertension amongst others in the USA. It is known to target sodium/hydrogen exchanger 5, acid-sensing ion channel 1, transient receptor potential cation channel subfamily V member 2, acid-sensing ion channel 3, acid-sensing ion channel 2, polycystic kidney disease 2-like 1 protein, short transient receptor potential channel 7, gonadotropin-releasing hormone receptor, transient receptor potential cation channel subfamily A member 1, alpha-2A adrenergic receptor, short transient receptor potential channel 6, sodium/hydrogen exchanger 2, sodium/hydrogen exchanger 3, and sodium/hydrogen exchanger 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Midamor (generic drugs available since 1986-01-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amiloride hydrochloride
Tradename
Company
Number
Date
Products
MIDAMORPadagisN-018200 RX1982-01-01
1 products, RLD
Amiloride hydrochloride
+
Hydrochlorothiazide
Tradename
Company
Number
Date
Products
MODURETIC 5-50Merck KGaAN-018201 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
amiloride hydrochloride and hydrochlorothiazideANDA2023-02-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ascitesHP_0001541D001201R18
cystic fibrosisEFO_0000390D003550E84
edema—D004487R60.9
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
hypokalemiaHP_0002900D007008E87.6
polyuriaHP_0000103D011141R35
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03D: Aldosterone antagonists and other potassium-sparing agents
— C03DB: Other potassium-sparing agents in atc
— C03DB01: Amiloride
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I103146620
Chronic renal insufficiencyD051436N18—1—2—3
Essential hypertensionD000075222I10———112
ProteinuriaD011507HP_0000093R801——1—2
PrehypertensionD058246——11—2
Type 2 diabetes mellitusD003924EFO_0001360E11———1—1
Bipolar disorderD001714EFO_0000289F30.9———1—1
Autosomal dominant polycystic kidneyD016891EFO_1001496Q61.2———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98——2——2
Insulin resistanceD007333EFO_0002614—11—12
Coronary diseaseD003327—11——1
Coronary artery diseaseD003324I25.1—11——1
Primary hyperparathyroidismD049950EFO_0008519E21.0—11——1
Sleep apnea syndromesD012891EFO_0003877G47.3——1——1
OverweightD050177E66.3—11——1
Nephrotic syndromeD009404EFO_0004255N04——1——1
EdemaD004487R60.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8411——13
Optic neuritisD009902EFO_0007405H46—2———2
Chronic progressive multiple sclerosisD020528—1———1
Migraine with auraD020325EFO_0005295G43.1—1———1
AlbuminuriaD000419EFO_0004285R80.9—1———1
Multiple sclerosisD009103EFO_0003885G35—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD0105991————1
Gastroesophageal refluxD005764EFO_0003948K211————1
HeartburnD006356R121————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Microvascular anginaD017566————11
Bone fracturesD050723EFO_0003931T14.8————11
Nephrogenic diabetes insipidusD018500N25.1————11
Diabetic nephropathiesD003928EFO_0000401————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAMILORIDE
INNamiloride
Description
Amiloride is a member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. It has a role as a sodium channel blocker and a diuretic. It is a member of pyrazines, an organochlorine compound, an aromatic amine and a member of guanidines. It is a conjugate base of an amiloride(1+).
Classification
Small molecule
Drug classepithelial sodium channel (ENaC) inhibitors, amiloride derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C(N)NC(=O)c1nc(Cl)c(N)nc1N
Identifiers
PDB4NTX
CAS-ID2609-46-3
RxCUI644
ChEMBL IDCHEMBL945
ChEBI ID2639
PubChem CID16231
DrugBankDB00594
UNII ID7DZO8EB0Z3 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC9A5
SLC9A5
ASIC1
ASIC1
TRPV2
TRPV2
ASIC3
ASIC3
ASIC2
ASIC2
PKD2L1
PKD2L1
TRPC7
TRPC7
GNRHR
GNRHR
TRPA1
TRPA1
ADRA2A
ADRA2A
TRPC6
TRPC6
SLC9A2
SLC9A2
SLC9A3
SLC9A3
SLC9A1
SLC9A1
Organism
Homo sapiens
Gene name
SLC9A5
Gene synonyms
NHE5
NCBI Gene ID
6553
Protein name
sodium/hydrogen exchanger 5
Protein synonyms
Na(+)/H(+) exchanger 5, NHE-5, solute carrier family 9 (sodium/hydrogen exchanger), member 5, Solute carrier family 9 member 5, solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), member 5
Uniprot ID
Q9Y626
Mouse ortholog
Slc9a5 (277973)
sodium/hydrogen exchanger 5 (B2RXE2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 16,139 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
11,324 adverse events reported
View more details